Oppenheimer initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $30 price target. The firm sees an “underappreciated opportunity” for the company’s lead asset denifanstat, a first-in-class fatty acid synthase inhibitor, in metabolic dysfunction-associated steatohepatitis, which it notes is expected to reach $15B in market potential. Opco anticipates a near-term catalyst upon Sagimet raising $200M of additional capital for the ongoing Phase 3 registrational trials by leveraging denifanstat’s competitive profile based on the Phase 2b data. It sees Sagimet ultimately benefiting from Madrigal Pharmaceuticals’ (MDGL) build-out of the MASH market as diagnosis rates and reimbursement improve.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences initiated with an Outperform at Oppenheimer
- Sagimet Biosciences price target lowered to $31 from $32 at JMP Securities
- Sagimet Biosciences participates ik,on No
- Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da
- Sagimet Biosciences Advances MASH Treatment with Denifanstat